Development of an integrated population pharmacokinetic model for oral levetiracetam in populations of various ages and ethnicities

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 1, 2014, Pages 61-68

  Toublanc, Nathalie ^a   Lacroix, Brigitte D ^a   Yamamoto, Junichi ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Anti epileptic; E Keppra; Epilepsy; Ethnicity; Japanese; Keppra; Levetiracetam; Pediatric; Population pharmacokinetics

Indexed keywords

ETIRACETAM;

ADOLESCENT; ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; EPILEPSY; ETHNIC GROUP; ETHNICITY; FEMALE; HUMAN; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NORTH AMERICA; NORTH AMERICAN;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AFRICAN AMERICANS; AGE FACTORS; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; EPILEPSIES, PARTIAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; JAPAN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NORTH AMERICA; PIRACETAM; YOUNG ADULT;

EID: 84898489017     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RG-045     Document Type: Article

References (32)

1. Ben-Menachem, E. and Falter, U.: Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia, 41: 1276-1283 (2000).
2. Cereghino, J. J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L. J. and Leppik, I.: Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology, 55: 236-242 (2000).
3. Shorvon, S. D., Löwenthal, A., Janz, D., Bielen, E. and Loiseau, P.: Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia, 41: 1179-1186 (2000).
4. Glauser, T. A., Ayala, R., Elterman, R. D., Mitchell, W. G., Van Orman, C. B., Gauer, L. J. and Lu, Z.: N159 Study Group: Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology, 66: 1654-1660 (2006).
5. Piña-Garza, J. E., Nordli, D. R., Jr., Rating, D., Yang, H., Schiemann-Delgado, J. and Duncan, B.: Levetiracetam N01009 Study Group: Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia, 50: 1141-1149 (2009).
6. Noachtar, S., Andermann, E., Meyvisch, P., Andermann, F., Gough, W. B. and Schiemann-Delgado, J.: N166 Levetiracetam Study Group: Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology, 70: 607-616 (2008).
7. Berkovic, S. F., Knowlton, R. C., Leroy, R. F., Schiemann, J. and Falter, U.: Levetiracetam N01057 Study Group: Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology, 69: 1751-1760 (2007).
8. French, J., di Nicola, S. and Arrigo, C.: Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy. Epilepsia, 46: 1304-1307 (2005).
9. Stockis, A., Lu, S., Tonner, F. and Otoul, C.: Clinical pharmacology of levetiracetam for the treatment of epilepsy. Expert. Rev. Clin. Pharmacol., 2: 339-350 (2009).
10. Patsalos, P. N.: Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther., 85: 77-85 (2000).
11. Perucca, E., Gidal, B. E. and Baltès, E.: Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res., 53: 47-56 (2003).
12. Gidal, B. E., Baltès, E., Otoul, C. and Perucca, E.: Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res., 64: 1-11 (2005).
13. Ramael, S., De Smedt, F., Toublanc, N., Otoul, C., Boulanger, P., Riethuisen, J. M. and Stockis, A.: Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin. Ther., 28: 734-744 (2006).
14. Pigeolet, E., Jacqmin, P., Sargentini-Maier, M. L. and Stockis, A.: Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin. Pharmacokinet., 46: 503-512 (2007).
15. Toublanc, N., Sargentini-Maier, M. L., Lacroix, B., Jacqmin, P. and Stockis, A.: Retrospective Population Pharmacokinetic Analysis of Levetiracetam in Children and Adolescents with Epilepsy. Dosing Recommendations. Clin. Pharmacokinet., 47: 333-341 (2008).
16. Strolin Benedetti, M., Whomsley, R., Nicolas, J. M., Young, C. and Baltès, E.: Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur. J. Clin. Pharmacol., 59: 621-630 (2003).
17. Pellock, J. M., Glauser, T. A., Bebin, E. M., Fountain, N. B., Ritter, F. J., Coupez, R. M. and Shields, W. D.: Pharmacokinetic study of levetiracetam in children. Epilepsia, 42: 1574-1579 (2001).
18. Fountain, N. B., Conry, J. A., Rodríguez-Leyva, I., Gutierrez-Moctezuma, J., Salas, E., Coupez, R., Stockis, A. and Lu, Z. S.: Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4-12 year old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Res., 74: 60-69 (2007).
19. Glauser, T. A., Mitchell, W. G., Weinstock, A., Bebin, M., Chen, D., Coupez, R., Stockis, A. and Lu, Z. S.: Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia, 48: 1117-1122 (2007).
20. Patsalos, P. N.: Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet., 43: 707-724 (2004).
21. Yagi, K., Kameyama, S., Kaneko, S., Murasaki, M. and Yamauchi, T.: Multicenter, double-blind, randomized, placebo-controlled study of levetiracetam as add-on therapy in Japanese patients with uncontrolled partial seizures. J. Jpn. Epil. Soc., 28: 3-16 (2010) (in Japanese).
22. Yagi, K., Kameyama, S., Kaneko, S., Murasaki, M., Yamauchi, T., Yoshida, K. and Suzuki, A.: A multicentre, open-labeled, follow-up trial of levetiracetam in Japanese epilepsy patients with partial onset seizures. J. Jpn. Epil. Soc., 29: 441-454 (2012) (in Japanese).
23. Beal, S. L., Sheiner, L. B., Boeckmann, A., Bauer, R. J.: NONMEM user's guide (1989-2009), Icon Development Solutions, Ellicott City.
24. Lindbom, L., Pihlgren, P. and Jonsson, E. N.: PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effects modeling using NONMEM. Comput. Methods Programs Biomed., 79: 241-257 (2005).
25. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org.
26. Holford, N. H.: A size standard for pharmacokinetics. Clin. Pharmacokinet., 30: 329-332 (1996).
27. Mahmood, I.: Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br. J. Clin. Pharmacol., 61: 545-557 (2006).
28. Ministry of Health, Labour and Welfare (NHLW) Japan. National growth survey on preschool children 2000.
29. Japanese Ministry of Education, Culture, Sports, Science and Technology. School health survey report 2000.
30. Regulation (EC) No 1901/2006 of the European Parliament and of the Council. 12 December 2006 with amendment 20 December 2006.
31. US Pediatric Research Equity Act (Public Law 108-155) 03 December 2003.
32. Toublanc, N., Lovern, M., Sargentini-Maier, M. L. and Stockis, A.: Population pharmacokinetic analysis of levetiracetam in pediatric patients with epilepsy aged 1 month to 16 years. Poster presented at the 8th European Congress on Epidemiology, Berlin 22-25 September 2008.